You are here: Home: BCU CME | 2005: Case 5: Select publications
 
     
 

SELECT PUBLICATIONS

Belfiglio M et al. Interdisciplinary Group for Cancer Care Evaluated (GIVIO) Group. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer 2005;104(11):2334-9. Abstract

Burstein HJ et al. Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors. Proc ASCO 2005;Abstract 529.

Cuzick J et al. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;[Epub ahead of print]. Abstract

Cuzick J, Howell A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. Proc ASCO 2005;Abstract 658.

Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82(Suppl 1):Abstract 4.

Howell A, Buzdar A. Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol 2005;93(2-5):237-47. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Howell A et al; ATAC Trialists’ Group. ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. San Antonio Breast Cancer Symposium 2004;Abstract 1.

Jakesz R et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc ASCO 2005;Abstract 527.

Johnston SR et al. Life following aromatase inhibitors — Where now for endocrine sequencing? Breast Cancer Res Treat 2005;93(Suppl 1):19-25. Abstract

Kalidas M, Brown P. Aromatase inhibitors for the treatment and prevention of breast cancer. Clin Breast Cancer 2005;6(1):27-37. Abstract

Making real progress against breast cancer. Some of the best cancer news this year has been the success of targeted approaches to treating breast cancer. Harv Women’s Health Watch 2005;13(2):1-3. No abstract available

Morales L et al. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 2005;17(6):559-65. Abstract

Nahleh ZA, Jazieh AR. Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer. Am J Clin Oncol 2005;28(6):631-3. No abstract available

Nordman IC et al. The aromatase inhibitors in early breast cancer: Who, when, and why? Med J Aust 2005;183(1):24-7. Abstract

Valentini M et al. Updated results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group for Cancer Care Evaluation study of adjuvant treatment in breast cancer 01 (SITAM 01). Proc ASCO 2005;Abstract 528.

Winer EP et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: Status Report 2004. J Clin Oncol 2005;23(3):619-29. Abstract

 

  
 
 
     
 
 


 
Editor’s Note:
Common questions about breast cancer from oncologists in community practice


Case 1: An active 79-year-old woman with a 7.5-centimeter, Grade II, ER/PR-positive, HER2-negative breast cancer with lymphovascular invasion and three positive nodes (from the practice of Dr Martha A Tracy)
- Select publications

Case 2: A 41-year-old premenopausal woman with an ER/PR-positive, HER2-positive infiltrating ductal carcinoma and six positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 3: A 68-year-old woman with disease progression 10 years after presenting with hormone receptor-positive diffuse metastatic disease to the bone (from the practice of Dr Ghaleb A Saab)
- Select publications

Case 4: A 91-year-old woman with dementia who was diagnosed with Stage II, ER-positive, lymph node-negative breast cancer 15 years ago and now has diffuse bone metastases (from the practice of Dr Juliann M Smith)
- Select publications

Case 5: A 41-year-old surgically postmenopausal woman with a 3.5-centimeter, ER/PR-positive, HER2-positive tumor and two positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 6: A 45-year-old premenopausal woman with a 0.7-cm, ER/PR-positive, HER2-positive tumor with 25 percent high-grade DCIS and an Oncotype DX™ recurrence score of 16 (from the practice of Dr Steven W Papish)
- Select publications

Case 7: A woman who presented in 1989 with an infiltrating lobular carcinoma and 21 positive nodes and was treated with adjuvant chemotherapy and tamoxifen and then develops metastatic disease and is treated over the next 11 years with a variety of chemotherapeutic and hormonal agents (from the practice of Dr Pamela Drullinsky)
- Select publications

Case 8: A 35-year-old woman with a 3.5-cm, ER/PR-positive, HER2-positive infiltrating ductal carcinoma and two positive sentinel lymph nodes treated on the nontrastuzumab- containing arm of the Intergroup N9831 trial (from the practice of Dr Pamela Drullinsky)
- Select publications
 
CME Information
Faculty Disclosures
Editor's Office